These findings could have implications for COX-2 targeted therapy in breast cancer and suggest that patients with ER-negative and HER2-positive tumors would benefit from a COX-2 targeted therapy with the efficacy of this therapy being strongest in patients with both an ER-negative tumor status and an amplification of HER2 leading to high HER2 expression. Here, ESR1 is linked to neoplasm.